Zai Lab Limited (ZLAB)
(Delayed Data from NSDQ)
$14.42 USD
+0.22 (1.55%)
Updated Apr 16, 2024 03:53 PM ET
After-Market: $14.40 -0.02 (-0.14%) 7:48 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ZLAB 14.42 +0.22(1.55%)
Will ZLAB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ZLAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLAB
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?
ZLAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals
Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up
Other News for ZLAB
A Risky Bet: Zai Lab's Uncertain Future
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
Executive officers of Zai Lab 'do not anticipate selling any shares' in 2024
ClearBridge International Growth ADR Strategy Q1 2024 Commentary